- Home
- DNTH vs KURA Comparison
DNTH vs KURA Comparison
Compare DNTH & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- KURA
- Stock Information
- Founded
- DNTH 2015
- KURA 2014
- Country
- DNTH United States
- KURA United States
- Employees
- DNTH N/A
- KURA N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNTH Health Care
- KURA Health Care
- Exchange
- DNTH Nasdaq
- KURA Nasdaq
- Market Cap
- DNTH 711.2M
- KURA 793.2M
- IPO Year
- DNTH N/A
- KURA N/A
- Fundamental
- Price
- DNTH $21.66
- KURA $7.39
- Analyst Decision
- DNTH Strong Buy
- KURA Strong Buy
- Analyst Count
- DNTH 9
- KURA 11
- Target Price
- DNTH $46.43
- KURA $27.89
- AVG Volume (30 Days)
- DNTH 285.9K
- KURA 1.5M
- Earning Date
- DNTH 11-07-2024
- KURA 02-25-2025
- Dividend Yield
- DNTH N/A
- KURA N/A
- EPS Growth
- DNTH N/A
- KURA N/A
- EPS
- DNTH N/A
- KURA N/A
- Revenue
- DNTH $5,366,000.00
- KURA N/A
- Revenue This Year
- DNTH $100.14
- KURA N/A
- Revenue Next Year
- DNTH N/A
- KURA $233.30
- P/E Ratio
- DNTH N/A
- KURA N/A
- Revenue Growth
- DNTH 51.41
- KURA N/A
- 52 Week Low
- DNTH $14.82
- KURA $6.98
- 52 Week High
- DNTH $33.77
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- DNTH 45.12
- KURA 22.90
- Support Level
- DNTH $18.72
- KURA $7.02
- Resistance Level
- DNTH $28.65
- KURA $7.66
- Average True Range (ATR)
- DNTH 2.31
- KURA 0.33
- MACD
- DNTH -0.33
- KURA 0.10
- Stochastic Oscillator
- DNTH 32.14
- KURA 21.58
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.